2 hrs ago
Aurobindo Arm Launches Adquey, Enters U.S. Dermatology Market
Acrotech Biopharma has introduced a medicine called Adquey in the United States.
Adquey is for people with mild-to-moderate atopic dermatitis, a skin condition.
The launch is Acrotech’s first move into the U.S. dermatology market.
The company is also creating a new team focused only on skin-care medicines.
This team will handle marketing, sales and work with health professionals.
Acrotech says it wants to build a dermatology business beyond just one product.
Adquey will compete in a market estimated at about $1.3 billion.
The company described the launch as an important milestone.
Acrotech Biopharma, a subsidiary of Aurobindo Pharma, launched Adquey in the United States.
Adquey is intended to treat mild-to-moderate atopic dermatitis.
The launch marks Acrotech’s entry into the U.S. dermatology market.
Acrotech established a dedicated dermatology business unit covering marketing, sales and field engagement.
The U.S. market for the treatment area is estimated at about $1.3 billion for the 12 months ending July 2026, according to IQVIA MAT.
- Who
- Acrotech Biopharma, a subsidiary of Aurobindo Pharma, launched Adquey.
- What
- Adquey was launched to treat mild-to-moderate atopic dermatitis, alongside the creation of a dedicated dermatology business unit.
- Where
- The United States.
- When
- The launch was reported on October 1, 2026.
- Why
- Acrotech aims to enter the U.S. dermatology market and build capabilities for additional dermatology opportunities.
Key facts
- Company
- Acrotech Biopharma, a subsidiary of Aurobindo Pharma
- Product
- Adquey
- Indication
- Mild-to-moderate atopic dermatitis
- Market
- U.S. dermatology market
- Market estimate
- About $1.3 billion for the 12 months ending July 2026
- Market data source
- IQVIA MAT
- New business unit
- Dedicated dermatology unit with marketing, sales and field-based capabilities
Quotes
Ashish Anvekar
President of Acrotech Biopharma
“We are building more than a commercial organization around a single product. We are establishing a dedicated dermatology platform designed to support Adquey today while creating the capabilities to pursue additional opportunities that can address important unmet needs in dermatologic care.”
thehindubusinessline.com
“The launch of Adquey is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis.”
thehindubusinessline.com
Sources
Related news
Cohance Lifesciences invests $18 million to expand ADC strategy
Sudarshan Pharma Proposes 9.5% MedTherapy Stake to Pursue Global Growth
RPG Life Sciences Plans ₹500 Crore Expansion Through Acquisitions
Broker Resumes Acutaas Chemicals Coverage With Buy, ₹3,800 Target
Arthritis Drug Shows Promise Restoring Hair in Severe Alopecia
Cipla Signs Exclusive Pact for Experimental Breast Cancer Drug
